Loading…
Maker of MRI-compatible IV infusion pumps and patient monitoring systems used during MRI procedures.
Maker of MRI-compatible IV infusion pumps and patient monitoring systems used during MRI procedures.
Sells the pump system to hospitals and gets recurring revenue from single-use IV sets used with every pump, so the installed base of pumps matters. Its pumps are designed to work inside the magnetic field of an MRI scanner, where ordinary electric pumps cannot be used.
Moat: narrow (IP / patents, regulatory licence). One of few makers of infusion pumps safe to use inside the MRI's magnetic field, a narrow regulated niche.
Headquarters: Winter Springs, Florida · Founded: 1992 · Employees: 166
Size IRadimed (IRMD) is a United States Health Care company (Medical Specialties) with a market value of $1.10B, the 2188th largest of 3,117 United States companies the cockpit tracks. Shares closed at $86.31 on 6 Nov 2026.
Performance Over six months the shares was unchanged, against -13.9% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 11.0% over the last twelve months (peer median +13.7%); the operating margin is 32.3% (peer median 7.2%).
Valuation It trades at 36.0× forward earnings against a peer median of 20.9× (4th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 43.4 points above its cost of capital (9.4% WACC).
Short interest Short interest is 5.2% of the free float (15 Oct 2026).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $89.3M | $83.8M | $73.2M | $65.6M | $53.3M |
| Revenue growth | — | +14% | +12% | +23% | — |
| Gross profit | $67.5M | $64.3M | $56.3M | $50.2M | $41.3M |
| EBITDA | $30.5M | $27.3M | $22.8M | $20.8M | $16.3M |
| Net income | $24.0M | $22.5M | $19.2M | $17.2M | $12.8M |
| Free cash flow | $26.1M | $17.2M | $17.6M | $6.02M | $9.22M |
| Capital expenditure | $1.54M | $8.42M | $8.82M | $8.01M | $1.87M |
| Total debt | $0 | $0 | $154,688 | $2.04M | $2.21M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| IRadimed IRMD | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
| Koninklijke Philips PHIA.AS | $29.8B | +24% | -1% | 10% | 16.5× | 5.7% |
| GE HealthCare GEHC | $37.2B | +30% | +7% | 14% | 15.4× | 4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IRMD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.5% | +1.0% | 11th highest of 21 |
| 6-month return | 0.0% | -13.9% | 8th highest of 20 |
| Distance from 52-week high | -20.0% | -35.4% | 3rd highest of 21 |
| Revenue growth (TTM) | +11.0% | +13.7% | 10th lowest of 20 |
| Operating margin | 32.3% | 7.2% | 3rd highest of 20 |
| Forward P/E | 36.0× | 20.9× | 4th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 19.1% | 7.7% | 2nd most demanding of 10 |
| Growth delivered (Del g) | +21.5% | +8.6% | highest of 10 |
| Hurdle (Req g minus delivered) | -2.3 pp | +1.3 pp | 4th least demanding of 10 |
| ROIC minus cost of capital | +43.4 pp | -5.8 pp | highest of 20 |
| EV / EBITDA | 34.1× | 23.6× | 2nd most expensive of 6 |
| Net debt / EBITDA | -2.1× | 4.9× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% | +21.5% |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 20.9× | 6.5% | +10.3% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | n/a | n/a | n/a |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | n/a | n/a | n/a |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 7% | 7.9× | -2.3% | +3.6% |
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -59% | n/a | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 12% | 55.2× | 12.4% | +12.9% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 213.2× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 15.0× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | n/a | 53.9% | +8.6% |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 18.8× | 7.7% | -2.9% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 5.8× | 5.2% | +3.6% |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | n/a | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | n/a | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 3,912.9× | n/a | n/a |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |